Hypopituitarism News and Research

RSS
Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

CNDA approves KEYTRUDA for treatment of advanced melanoma

CNDA approves KEYTRUDA for treatment of advanced melanoma

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

Opdivo plus low-dose Yervoy shows promising results in treating renal cell carcinoma patients

First-ever treatment for Merkel cell carcinoma receives approval in Japan

First-ever treatment for Merkel cell carcinoma receives approval in Japan

Newly-identified autoimmune endocrine disease is caused by thymomas, study finds

Newly-identified autoimmune endocrine disease is caused by thymomas, study finds

People with reduced oxytocin levels perform worse on empathy tasks, new research shows

People with reduced oxytocin levels perform worse on empathy tasks, new research shows

Endocrine Society issues new guidelines on hypopituitarism

Endocrine Society issues new guidelines on hypopituitarism

Blast-related concussions result in hormone changes that lead to poor quality of life among veterans

Blast-related concussions result in hormone changes that lead to poor quality of life among veterans

Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck announce another immuno-oncology collaboration

Lilly, Merck expand oncology clinical trial collaboration

Lilly, Merck expand oncology clinical trial collaboration

PET/CT may improve differentiation of PTSD from MTBI

PET/CT may improve differentiation of PTSD from MTBI

New Clinical Practice Guideline for diagnosis, treatment of acromegaly

New Clinical Practice Guideline for diagnosis, treatment of acromegaly

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Bristol-Myers Squibb to present new immunotherapy study data at ASCO Annual Meeting

Study: About 42% of screened veterans with blast injuries have irregular hormone levels

Study: About 42% of screened veterans with blast injuries have irregular hormone levels

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

NICE decides to recommend Bristol-Myers Squibb’s YERVOY for treatment of advanced melanoma

New guidelines for the treatment of acromegaly, a serious growth hormone disorder

New guidelines for the treatment of acromegaly, a serious growth hormone disorder